Skip to main content

Remote Job Finders (RJF)

Sutro Cuts Half of Staff, Deprioritizes ADC in Strategic Review

Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate luveltamab tazevibulin, which it was studying for ovarian cancer. The biotech will seek licensing opportunities for the asset.

“Perfect Patient” Industry Burdens; Exits and Investment in Women’s Health

In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis and Miruna Sasu, CEO of COTA, discuss the challenges of inclusion and exclusion criteria of clinical trial patients, and reflect on current investment approaches around women’s health.
Scroll to top